TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04009759
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
Study: NCT04933383
Drug: AQ001S 0.125 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered by nebulization once daily
Study: NCT05819970
Drug: Allium Sativum Oil
Normalized name: Allium sativum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allium sativum oil will be used as non-vital pulpotomy medicament
Study: NCT05524389
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous concurrent or sequential adjuvant chemotherapy consists of carboplatin/paclitaxel, cisplatin/doxorubicin or cisplatin/doxorubicin/paclitaxel, etc.
Study: NCT05224128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules (similar appearance with imatinib) without active substance have to be taken orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
Study: NCT05731518
Drug: SC0245
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC0245 Quaque Die(QD) administered with a 3-day on and 4-day off schedule in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
Study: NCT05637216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 25 milligram oral capsule
Study: NCT05383183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06512753
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX (16) is given at a dose of 15 mg per week, orally or subcutaneously. Additionally, folate supplementation is administered concurrently as part of standard care, with folate 10 mg/week administered 24 hours after MTX intake.
Study: NCT05641298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT04982289
Drug: ALXN1830
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an SC infusion.
Study: NCT04135092
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Study: NCT06534320
Drug: Placebo of DA-302168S
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 2 subjects receive placebo of DA-302168S tablets.
Study: NCT06534320
Drug: Placebo of DA-302168S
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 2 subjects receive study placebo of DA-302168S tablets.
Study: NCT06281964
Drug: PLB1004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received oral PLB1004 240mg on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive oral PLB1004 240mg and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Study: NCT04583735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05223400
Drug: Clindamycin Injection
Normalized name: clindamycin Injection
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: it is a clindamycin use evaluation study
Study: NCT06301074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined.
Study: NCT05579431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration.
Study: NCT05579964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priming dose of NaCl 0.9% in a 5 ml syringe mixed in priming fluid and NaCl 0.9% 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
Study: NCT06108024
Drug: SM-020 gel 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
Study: NCT06108024
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
Study: NCT05862623
Drug: AER-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: AER-01 solution for inhalation delivered via nebulizer
Study: NCT05862623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for solution for inhalation delivered via nebulizer
Study: NCT05474014
Drug: intravenous patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics will be given using a patient-controlled analgesia device.
Study: NCT05435027
Drug: GRT-R912, samRNA-Spikebeta-TCE11
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection of GRT-R912. Doses will be decided after safety review of Part A.
Study: NCT05435027
Drug: GRT-R914, samRNA-Spikebeta-TCE9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 3 microgram (mcg), 10 mcg, or 30 mcg intramuscular (IM) injection of GRT-R914.~Part C: IM injection of GRT-R914. Doses decided after safety review of Part A.
Study: NCT05435027
Drug: GRT-R918, samRNA-SpikeOmicron-N-TCE11
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection of GRT-R918. Doses will be decided after safety review of Part A.
Study: NCT06188715
Drug: Placebo MOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for moxidectin
Study: NCT05382208
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100 mg orally twice a day.
Study: NCT05382208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo orally twice a day.
Study: NCT05023915
Drug: diammonium glycyrrhizinate enteric-coated capsule
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg tid for 3 months
Study: NCT06211309
Drug: co.mouthwas
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
Study: NCT05952102
Drug: Nigella Sativa Oil capsule
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella Sativa Oil as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia
Study: NCT05774067
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient received noradrenaline infusion at rate 0.1 mcg/kg/min. with deflation of tourniquet
Study: NCT06031090
Drug: Normal Saline 10 mL Injection
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous 10 ml normal saline 20 minutes before spinal anesthesia
Study: NCT05982470
Drug: Estradiol Gel
Normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application) for 12 months
Study: NCT06016400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06517641
Drug: Haploidentical donor bone marrow transplant
Normalized name: Sus scrofa bone marrow preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1. HSCT: Eligible patients will receive a haploidentical donor bone marrow transplant.
Study: NCT06517641
Drug: Unrelated donor bone marrow transplant
Normalized name: Sus scrofa bone marrow preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1. HSCT: Eligible patients will receive an unrelated donor bone marrow transplant.
Study: NCT03896815
Drug: INCB054329
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06254183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo is a sham medical treatment that appears to be a real medical intervention but has no therapeutic effect. It is often used in clinical trials to compare the effects of a new treatment to those of a placebo. Common examples of placebos include inert tablets (like sugar pills), inert injections (like saline), and even sham surgery or other procedures. Placebos are typically made of inactive substances such as starch or sugar and are designed to be indistinguishable from the actual treatment
Study: NCT04762758
Drug: (RS)-baclofen, naltrexone hydrochloride and D-sorbitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral fixed dose combination
Study: NCT04762758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid oral solution
Study: NCT05455697
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05455697
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05861570
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided injection using 3ml normal saline
Study: NCT05861570
Drug: (Sodium Hyaluronate (Hyruan One , LG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided injection using 3ml of Sodium Hyaluronate
Study: NCT05152849
Drug: AXA1125
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXA1125 administered BID with or without food
Study: NCT05152849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo administered BID with or without food
Study: NCT05403359
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Description of the intervention in each of the work packages:~* WP1A admission: Steroid dose \>6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~* WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (\> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~* WP2 ICU admission: High-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~* WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) or no steroids up to day 28.
Study: NCT06062641
Drug: SR-GDP
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 40mg/d，po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg，po/iv d1-4 (If patient\>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
Study: NCT05340231
Drug: TACE protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial infusion chemotherapy: Oxaliplatin(85mg/m\^2)+Raltitrexed(3mg) Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)，The endpoint for embolization was defined as stagnation of blood flow of the posterior mesenteric artery.~Intervention cycle：4W; Treatment times: 2. followed by mFOLFOX6
Study: NCT04352400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously as a continuous infusion
Study: NCT04877756
Drug: OLX10010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized cake reconstituted with WFI and injected intradermally
Study: NCT04794218
Drug: rVSV∆G-LASV-GPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 10\^5 pfu delivered intramuscularly
Study: NCT04794218
Drug: rVSV∆G-LASV-GPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 10\^6 pfu delivered intramuscularly
Study: NCT04736485
Drug: perioperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT + Spartalizumab
Study: NCT06053424
Drug: [11C]AZ14132516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand
Study: NCT06052332
Drug: Adjuvant chemotherapy (optional)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of the adjuvant chemotherapy is to the investigator's discretion.
Study: NCT04505358
Drug: PU-AD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active vs placebo
Study: NCT04755920
Drug: SGM-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorescence-guided surgery
Study: NCT04814108
Drug: ZN-c3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-c3 is an investigational drug.
Study: NCT04314375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily.
Study: NCT06609187
Drug: GNC-077
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06699459
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ① Capecitabine, 1250mg/m2 orally, bid, Q3W, d1-14;
Study: NCT05940298
Drug: Intravenous injection of [99mTc]Tc-DB8
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single intravenous injection of \[99mTc\]Tc-DB8, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Study: NCT06387966
Drug: flunotinib
Normalized name: ilunocitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day one will be used for drug administration, and Day two\~Day seven will be used for experimental data collection.
Study: NCT05769816
Drug: NAs
Normalized name: DNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once/day, 1 capsule/time, oral
Study: NCT04809623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match edecesertib tablets administered orally
Study: NCT05076110
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day
Study: NCT05076110
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day
Study: NCT05211232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
Study: NCT04809623
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)
Study: NCT05390905
Drug: HSK21542 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1μg/kg/dose
Study: NCT05390905
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05335044
Drug: EX5619
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT04642287
Drug: Topical 5FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
Study: NCT05948813
Drug: TY-9591
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
Study: NCT05580003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension
Study: NCT06476119
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant chemotherapy according to local/ national guidelines
Study: NCT05309200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.
Study: NCT06597058
Drug: MAR
Normalized name: Marax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tablet
Study: NCT06698926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05980507
Drug: ICI201
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI201 CAR-T cell injection
Study: NCT05319041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5g maltodextrin without any herbs medicine
Study: NCT04329221
Drug: Topical 5FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
Study: NCT05357820
Drug: AB-106, Rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21
Study: NCT06121375
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered.
Study: NCT06299670
Drug: Combinations
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Of Thalidomide \& Hydroxyurea
Study: NCT06079164
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy administered intravenously
Study: NCT02533232
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 200mg per day
Study: NCT05461053
Drug: LMX 4 Topical Cream
Normalized name: LMX 4 Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
Study: NCT05213312
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles
Study: NCT04931524
Drug: carbon-14-[14C]-ANG-3777
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
Study: NCT05305508
Drug: Calcium Dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
Study: NCT05794659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.d. (3-week interval, 3 cycles in total)
Study: NCT05842382
Drug: Active Ingredient
Normalized name: TITANIUM DIOXIDE 79 mg in 1 g / ZINC OXIDE 67 mg in 1 g TOPICAL STICK [SPF 50 plus Sunscreen All Mineral Active Ingredients]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Vitamin C (12g/day)
Study: NCT05842382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dextrose 5%
Study: NCT03315299
Drug: ASP2215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will take ASP2215 by mouth daily for 28 day cycles
Study: NCT06699121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule QD oral administration
Study: NCT05732727
Drug: Antihypertensive algorithm
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive algorithm based on diuretics agents
Study: NCT06700083
Drug: SHR-6934 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-6934 placebo
Study: NCT06699108
Drug: VGR-R01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal injection of VGR-R01 (0.1 mL)
Study: NCT05732727
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care management for antihypertensive therapy intensification